A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Sponsor: MedImmune LLC

Sponsor score: 0

ClinicalTrials ID:NCT02671435

This study evaluates the safety and efficacy of durvalumab and monalizumab in advanced solid tumors through dose escalation, expansion, and exploration phases. Eligible participants have recurrent/metastatic cancer with measurable lesions. Exclusions include prior immunotherapy. Interventions include IV infusions of monalizumab, durvalumab, cetuximab, mFOLFOX6, and bevacizumab.

Patient Parameters

Program Overview

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).

Description

The study consists of 3 parts: dose escalation (Part 1), dose expansion (Part 2), and dose exploration (Part 3). Part 1 will evaluate dose escalation of durvalumab in combination with monalizumab in adult participants with select advanced solid tumor malignancies. Part 2 will evaluate further the identified dose of durvalumab in combination with monalizumab from Part 1 in adult participants with select advanced solid tumor malignancies. Part 3 will evaluate dose exploration of durvalumab in combination with monalizumab and standard of care systemic therapy with or without biological agent, and monalizumab in combination with biological agent in adult participants with CRC.

Eligibility Criteria

Inclusion Criteria

  1. Participants must have histologic documentation of advanced recurrent or metastatic cancer.
  2. Participants must be at the recurrent/metastatic setting, with selected advanced solid tumors.
  3. Participants must have at least one lesion that is measurable by RECIST v1.1
  4. Part 3, Dose exploration, CRC participants can be treatment naïve but should not have received more than two line of systemic therapy in the recurrent/metastatic setting.

Exclusion Criteria

  1. Prior treatment with immunotherapy agents. Prior treatment with antitumor vaccines may be permitted upon discussion with the medical monitor.
  2. Prior participation in clinical studies that include durvalumab alone or in combination, where the study has registrational intent and the analyses for the primary endpoint have not yet been completed
  3. Receipt of any conventional or investigational anticancer therapy within 4 weeks prior to the first dose of study treatment
  4. Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.

Locations

FACILITYZIPCITYSTATE
Research Site35233BirminghamAlabama
Research Site85258ScottsdaleArizona
Research Site91010DuarteCalifornia
Research Site92093La JollaCalifornia
Research Site90089Los AngelesCalifornia
Research Site95817SacramentoCalifornia
Research Site90404Santa MonicaCalifornia
Research Site80045AuroraColorado
Research Site33612TampaFlorida
Research Site60611ChicagoIllinois

Get This Program In Your Inbox

You can sign up and apply your patients for this program.